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Background: Polybasic helical peptides, such as peptide p5, bind human amyloid extracts and synthetic
amyloid ﬁbrils. When radiolabeled, peptide p5 has been shown to speciﬁcally bind amyloid in vivo
thereby allowing imaging of the disease. Structural requirements for heparin and amyloid binding have
been studied using analogues of p5 that modify helicity and chirality.
Methods: Peptide-ligand interactions were studied using CD spectroscopy and solution-phase binding
assays with radiolabeled p5 analogues. The interaction of a subset of peptides was further studied by
using molecular dynamics simulations.
Results: Disruption of the peptide helical structure reduced peptide binding to heparin and human
amyloid extracts. The all-D enantiomer and the β-sheet-structured peptide bound all substrates as well
as, or better than, p5. The interaction of helical and β-sheet structured peptides with Aβ ﬁbrils was
modeled and shown to involve both ionic and non-ionic interactions.
Conclusions: The α-helical secondary structure of peptide p5 is important for heparin and amyloid
binding; however, helicity is not an absolute requirement as evidenced by the superior reactivity of a β-
sheet peptide. The differential binding of the peptides with heparin and amyloid ﬁbrils suggests that
these molecular interactions are different. The all-D enantiomer of p5 and the β-sheet peptide are
candidates for amyloid targeting reagents in vivo.
General Signiﬁcance
Efﬁcient binding of polybasic peptides with amyloid is dependent on the linearity of charge spacing in
the context of an α-helical secondary structure. Peptides with an α-helix or β-sheet propensity and with
similar alignment of basic residues is optimal.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Amyloid is a complex pathology in which proteinaceous ﬁbrils,
composed of proteins or peptides with a cross-β-sheet secondary
structure, deposit in organs and tissues in association with cell-de-
rived hypersulfated heparan sulfate proteoglycans, serum amyloid PB.V. This is an open access article u
hroism; SPR, surface plasmon
transthyretin-associated
PP, islet amyloid-associated
ical Center, 1924 Alcoa High-component (SAP) and other accessory molecules [1,2]. The presence
of extracellular ﬁbrils, heparan sulfate proteoglycan and SAP are
pathognomonic of amyloid. The deposition of amyloid is associated
with a growing number of diseases including Alzheimer's disease,
type 2 diabetes and plasma cell dyscrasias, and it is also a con-
sequence of aging [3]. Amyloid accumulates in organs and tissues
leading to architectural damage, toxicity and ultimately dysfunction
[4]. Fibrils, like heparan sulfate (HS) glycosaminoglycans and heparin,
are ionic polymers composed of repeating subunits. Additionally, the
HS found associated with amyloid is structurally and electro-
chemically distinct from that found expressed ubiquitously in healthy
tissues – it is hypersulfated akin to heparin [5–7]. These unique
biochemical features, the abundance of polyelectrolytic ﬁbrils and
hypersulfated HS, serve as speciﬁc biomarkers for pathologic amyloidnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Peptide primary structure and physical data.
Peptide Mw AA % Helixa Primary structure
p5 3257.7 31 2.60 GGGYS KAQKA QAKQA KQAQK AQKAQ AK-
QAK Q
p5(D) 3257.7 31 nd [GGGYS KAQKA QAKQA KQAQK AQKAQ AK-
QAK Q]D
p5(sheet) 2106.6 18 0.05 VYKVK TKVKT KVKTK VKT
p5(coil) 2491.7 31 0.02 GGGYS KGGKG GGKGG KGGGK GGKGG
GKGGK G
p5(Pro3) 3221.7 31 0.23 GGGYS KAQKA PAKQA KQPQK AQKAP AK-
QAK Q
a Helix content predicted of peptide, based on amino acid sequence, using
Agadir (http://agadir.crg.es/) with parameters of; pH¼7; temperature 298 K, and;
an ionic strength of 0.15 [29]. nd, not determined.
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The heparin-binding peptide, p5, is a 31-residue synthetic re-
agent that contains a heptad repeat of amino acids (-KAQKAQA-),
and it has been shown to speciﬁcally bind inﬂammation-asso-
ciated AA amyloid and synthetic amyloid ﬁbrils in vitro [9,11].
Furthermore, when radiolabeled, p5 can be used to speciﬁcally
detect AA amyloid deposits in vivo in a murine model demon-
strating little or no reactivity with normal tissue [12,13]. Ad-
ditionally, peptide p5 binds synthetic amyloid ﬁbrils composed of
amyloidogenic immunoglobulin variable domain proteins that, in
contrast to tissue amyloid, lack HS proteoglycans [11]. The re-
activity of peptide p5 with amyloid ﬁbrils, puriﬁed human amyloid
extracts, and heparin is dependent upon ionic interactions with
negatively charged determinants on the glycosaminoglycans and
acidic amino acid sidechains in the ﬁbril polymer [10,14]. Peptide
p5þ14, a polybasic reagent based on the structure of p5 but with
an increased net charge, offers new promise as an amyloid-ima-
ging agent for detecting systemic amyloidosis in patients [15].
Efﬁcient binding of peptides to heparin, and presumably other
ionic polymers such as amyloid ﬁbrils and amyloid-associated HS,
is critically dependent upon the presence of basic amino acids,
lysine or arginine (and protonated histidine), and their spatial
orientation as governed by the secondary structure of the peptide
[16,17]. Synthetic polybasic peptides that can adopt a helical sec-
ondary structure, presenting the basic side chains aligned along
one face of the peptide, are optimal for binding to heparin [17] and
for the speciﬁc reactivity with AA tissue amyloid in mice [9]. In-
deed, the secondary structure of the peptide and the spacing of the
basic amino acids is of more importance than the total number of
basic amino acids or the net charge of the peptide [9].
To further probe the structural requirements for efﬁcient
amyloid binding by synthetic polybasic peptides and explore novel
structural variants, we have generated analogues of peptide p5
that: (i) disrupt the helical secondary structure by using glycine
residues that favor a disordered secondary structure or by insert-
ing three proline residues spaced along the peptide; (ii) have a
propensity for β-sheet structure by using valine and threonine
residues to separate the positively charged amino acids, and; (iii)
potentially exhibit greater in vivo stability by using all D-amino
acids. Structural analyzes and binding studies were used to com-
pare the binding of these variants with amyloid related substrates
and heparin quantitatively with the goal of deﬁning properties
that might be manipulated to optimize speciﬁc amyloid targeting.2. Materials and methods
2.1. Peptides and proteins
Peptides p5, p5(D), p5(sheet), p5(coil), and p5(Pro3) (Table 1) were
purchased from Keck Laboratories (New Haven, CT) or Anaspec
(Fremont, CA) as 70% pure preparations and further puriﬁed by
RP-HPLC (Biologic DuoFlow; BioRad, Hercules, CA) by using a
Zorbax™ 300SB-C3 solid phase (Agilent, Santa Clara, CA) with a
linear gradient of 1–51% acetonitrile in water with 0.05% v/v tri-
ﬂuoroacetic acid as the mobile phase (ﬂow rate of 4 mL/min).
Fractions of 1.8 mL-volume were collected, pooled, and the purity
and integrity of the peptides veriﬁed by mass spectrometry [18].
The Aβ(140) peptide and human islet amyloid polypeptide
(IAPP) were purchased from Anaspec as 490% pure preparations
and were used without further puriﬁcation.
Recombinant Vλ6 protein Wil was prepared from a periplasmic
extract of transformed E. coli and puriﬁed as previously described
[19].2.2. Human AL and ATTR extract preparation
Puriﬁed human amyloid tissue extracts were prepared using
autopsy-derived tissues from patients with light chain – (AL) or
transthyretin-associated (ATTR) amyloidosis using the water ﬂo-
tation method as described by Pras et al. [20] without modiﬁca-
tion. Puriﬁed amyloid material isolated in the water wash, and
amyloid rich pellet, was collected and stored lyophilized at RT
until used.
2.3. Preparation of synthetic amyloid ﬁbrils
To prepare synthetic amyloid ﬁbrils from rVλ6Wil, a 1 mL-vo-
lume containing 1 mg/mL of monomer in phosphate-buffered
saline (PBS), 0.01% w/v NaN3, pH7.5, was ﬁltered through 0.2 mm
pore-sized ﬁlter, added to a 15 mL conical polypropylene tube (BD
BioSciences, Bedford, MA) and shaken at a 45° angle at 225 rpm
for 3–5 d at 37 °C until the reaction mixture became opaque [19].
For Aβ(140) and IAPP ﬁbrils, ﬁltered 1 mL volumes of 0.2 mg/mL
peptide in PBS with 0.01% w/v NaN3, pH7.5, were placed at 37 °C
without shaking for 510 d. The presence of amyloid ﬁbrils was
conﬁrmed by using a thioﬂavin T (ThT; Sigma-Aldrich, St. Louis,
MO) ﬂuorescence emission assay. Brieﬂy, a suspension of ﬁbrils at
50 mg/ mL was prepared and 100 mL (5 mg) of the ﬁbril suspension
was added to each of three wells on a 96-well microplate. Thirty
mL of PBS was added to each of the wells prior to the addition of
10 mL of 300 mM ThT (Sigma-Aldrich, St. Louis, MO). A set of tri-
plicate wells containing PBS and ThT only was used as a back-
ground control. The ThT ﬂuorescence emission (490 nm, excitation
at 450 nm) was measured using a ﬂuorescence plate reader (Victor
1420 multilabel counter, Perkin Elmer, Wellesley, MA) and cor-
rected by subtraction of mean background ﬂuorescence. Fibril
preparations were aliquoted into single use volumes and stored at
80 °C.
2.4. Preparation of murine liver homogenates
The livers from 2 mice with inﬂammation-associated (AA)
amyloidosis or 2 healthy (WT) mice were harvested at necropsy.
Approximately 0.5 g of each AA or WT liver was removed, pooled
and a 10-fold volume of PBS added. Serine protease inhibitors,
leupeptin and phenylmethylsulfonyl ﬂuoride (PMSF), were added
each at 100 mg/mL. The solution was mixed vigorously (310 s
bursts) with a Polytron at setting 6 (Kinematica Inc., Bohemia, NY)
and then centrifuged at 4000 g for 10 min. The supernatant was
discarded and the pellet resuspended in a 10-fold volume of PBS
with 0.05% tween-20% and 0.05% NaN3. The solution was mixed
vigorously again by using the Polytron and the resulting suspen-
sion stored at 4 °C until used in pull down assays described below.
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The binding of p5-related peptides to rVλ6Wil ﬁbrils was
measured using a Biacore X surface plasmon resonance instru-
ment (GE Healthcare, Pittsburgh, PA) and all reagents were ob-
tained from GE Healthcare.
Fibrils were attached to CM-5 chips using the amino-coupling
method supplied with the instrument software. Brieﬂy, chips were
activated by injection (35 mL) of a mixture of N-ethyl-N′-(diethy-
laminopropyl) carbodiimide/ N-hydroxysuccinimide (EDC/NHS) at
a ﬂow rate of 5 mL/min. Immediately thereafter, 35 mL of rVλ6Wil
ﬁbrils freshly sonicated for 10 s with a microprobe and Tekmar
sonic disruptor, diluted to 100 mg/mL in pH 4.5 NaOAc buffer, was
injected. After the coupling reaction, the remaining active groups
on the chip were blocked by injection of 35 mL of 1 M ethanola-
mine-HCl pH 8.5. Non-ﬁbrillar rVλ6Wil was coupled to the Fc-2
channel and served as a control for non-speciﬁc binding to the
protein. A sensorgram was initiated on each chip in HBS-EP buffer
at 10 mL per min. An initial regeneration step consisting of a 5 mL
injection of glycine-buffered 1 M NaCl, pH 1.5, was performed and
the baseline allowed to re-equilibrate before beginning data col-
lection. Test peptides, p5, p5(D), p5(sheet), p5(coil), and p5(Pro3) were
diluted from stock solutions to 300 nM in HBS-EP buffer (0.01 M
HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20)
immediately before injection. The peptides were injected (50 mL)
and the data collected for 5 min followed by a 200 s delayed wash
cycle. The chip was subjected to a regeneration step before the
next test injection. Binding and washout data were extracted from
the sensorgram, aligned, and analyzed with the BIAevaluation
software (Ver. 3) by ﬁtting to a two-state binding model with
conformational change [AþB¼AB¼AB*] or a 1:1 Langmuir iso-
therm [AþB¼AB]. In the latter, the association rate is ﬁt to
R¼Req(1-e-(kaCþkd)(t-t0))þRI, where Req¼( kaC/kaC þ kd) Rmax and
further where, ka and kd are the association and dissociation rate
constants, respectively; Rmax, maximum analyte binding capacity;
C, concentration of analyte (M); t0 , injection start time; RI, bulk
refractive index contribution. The Langmuir dissociation model
equation being R¼R0e-kd(t-t0)þOffset, where, R0, is the response at
the start of the ﬁtted data; and Offset, is the response at inﬁnite
time. .
2.6. Circular dichroism (CD) spectroscopy
Circular dichroism spectra of peptides p5, p5(D), p5(sheet),
p5(coil), and p5(Pro3) (0.05 mg/mL in PBS) were acquired using a
dual detector DSM 1000 CD instrument (Olis Inc., Bogart, Georgia)
with a peptide sample volume of 2.9 mL and a 1 cm cuvette path
length. Data were collected in triplicate over the 190 nm 250 nm
wavelength range with 1 nm increments. Secondary structure
transitions were induced by addition of 2,2,2 triﬂuoroethanol (TFE)
up to 40% by volume or porcine low molecular weight heparin
(Enoxaparin sodium – Sanoﬁ, Bridgewater, NJ) up to 1.5 mg/mL (w/
v) ﬁnal concentration. Spectra were corrected for background by
subtraction of appropriate buffer control spectrum. Mean residue
ellipticity [θ] was calculated according to, [θ]¼θ*(MW/no. AA)/
(10*conc.*l), where: θ is ellipticity (millidegrees); MW is the mo-
lecular weight of the peptide; no. AA, is the number of amino acid
residues; conc. is the peptide concentration (mg/mL), and; l, is the
cuvette path length (cm).
2.7. Peptide radiolabeling for pulldown assays
In preparation for in vitro pull-down assays, 50 mg each of
peptides p5, p5(D), p5(sheet), p5(coil) and p5(Pro3) was radioiodinated
with 1 mCi of iodine-125 (125I – Perkin Elmer, Waltham, MA)
using 20 mg chloramine T as the oxidizing agent [21]. Afterquenching the reaction with 20 mg sodium metabisulﬁte, the
radiolabeled peptides were diluted into 0.1% sterile gelatin in PBS
and free radioiodine removed by size exclusion chromatography
on a 5-mL Sephadex G-25 (PD10; GE Healthcare) solid phase,
equilibrated with 0.1% gelatin/PBS. Fractions of 200 mL-volume
were collected, and those containing the maximal radioactivity
(indicative of 125I-labeled peptide) were pooled and the product's
radiochemical purity was established by SDS polyacrylamide gel
electrophoresis (PAGE) analyzed by phosphor imaging (Cyclone
Storage Phosphor System, Perkin Elmer, Shelton, CT).
2.8. Peptide-substrate binding studies – Pulldown assay
Fifty mg of ALκ, ALλ or ATTR amyloid extract, or 25 mg of syn-
thetic ﬁbrils composed of rVλ6Wil Aβ(140) or IAPP, suspended
in 200 mL of PBS with 0.05% tween-20 (PBST) were centrifuged in a
0.5 mL microfuge tube at 21,000 g for 10 min. The supernatant
was discarded and pellet resuspended in 200 mL of either PBS or
phosphate-buffered 1.5 M NaCl, both supplemented with 0.05%
tween-20. Ten microliters of a 1:100 dilution of 125I-labeled pep-
tide (100,000 counts per minute [CPM]; 5 ng peptide) stock
was added to the suspension of ﬁbrils or amyloid extract. The
sample was mixed by rotation at RT for 1 h. Samples were then
centrifuged twice at 15,000 g for 10 min. Supernatants and pel-
lets were separated after each step and the radioactivity in each
was measured using a Cobra II gamma counter (Perkin Elmer) with
a 1 min acquisition. The percentage of 125I-labeled peptide bound
to pellet was determined according to: Bound peptide¼[Pellet
CPM/(Pellet CPMþSupernatant CPM)]100.
For binding to liver homogenates, 25 mL (5 mg) of tissue was
centrifuged at 21,000 g for 5 min. The supernatant was dis-
carded, and the pellet resuspended in 200 mL PBST and the assay
performed as described above.
2.9. Competition pulldown assays
Competition pulldown assays were performed, as described
above using rVλ6Wil ﬁbrils as the substrate. In each case,
125I-labeled peptide (p5, p5(D), p5(sheet), p5(coil), and p5(Pro3)) was
mixed with a 1000-fold molar excess of unlabeled p5 and added to
the ﬁbrils. Bound peptide was measured as described above. The
assays were performed in triplicate and the data presented as the
mean of the % maximum value (bound peptide in the absence of
competitor) 795% conﬁdence intervals.
2.10. Computer modeling of peptide binding to amyloid ﬁbrils
To obtain initial structures for molecular dynamics (MD) si-
mulations, the ZDOCK server (http://zdock.umassmed.edu/) was
used to generate 100 theoretical models of the interaction of
peptides p5, p5(sheet) and p5(coil) with amyloid ﬁbrils composed of
Aβ(17-42) (PDB # 2BEG) [22]. ZDOCK searched all possible binding
modes in the translational and rotational space between the
peptide and ﬁbril and evaluated each pose using an energy-based
scoring function. The lowest energy peptide and Aβ(17-42) ﬁbril
complex was ﬁrst solvated in a TIP3P water box and then sub-
jected to 10 ns of molecular dynamics (MD) simulation using
NAMD 2.9 [23] with the CHARMM C36 force ﬁeld [24]. In the si-
mulation, the van der Waals interaction was smoothly turned off
between 8.5 and 10 Å using a switching function. Long-range
electrostatic interactions were treated using the Particle-Mesh
Ewald (PME) method [25] with a 1.0 Å grid spacing. The time step
for integration was 1 fs. Langevin dynamics was used to maintain a
constant temperature at 310 K, while the Nosé-Hoover Langevin-
piston algorithm was used to maintain a constant pressure at
1 bar.
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(MM-PB/SA) method [26,27] was used to compute the binding free
energies of the peptide with the Aβ(1742) ﬁbril. The total
binding energyΔGbind (app) was deﬁned asΔGbind (app)¼Gcomplex
GreceptorGligand. Each free energy term consisted of the gas phase
molecular mechanics energy (ΔEgas), the solvation free energy
(ΔGsol), and the vibrational entropy contributions (TΔS). ΔGsol
was estimated from the Poisson-Boltzmann (PB) theory and sol-
vent accessible surface area (SASA) calculations which yielded
ΔGpolar and ΔGnonpolar. In the PB, energies were evaluated at 0.1 M
NaCl concentrations. A surface tension coefﬁcient (γ) of
0.0072 kcal/(mol Å2) was used to calculate the nonpolar solvation
free energy contribution. Due to its prohibitive computational cost
and the inherent difﬁculty in determining accurate absolute en-
tropy for large protein-peptide complex systems, the vibrational
entropy contribution was not included in our calculation. Egas and
ΔGsol were computed for 1000 snapshots extracted evenly from
the last 2 ns of the MD trajectory.
2.11. Statistical methods
Binding data for ﬁbrils, extracts and tissue homogenates (Fig. 5)
were compared between each respective peptide and peptide p5
using one-way ANOVA. A Bonferroni correction was employed to
account for experiment-wise error rates associated with testing
multiple hypotheses concurrently. Statistical signiﬁcance was as-
sumed at a corrected alpha (α) value of 0.001. In Fig. 6, the 95%
conﬁdence intervals were calculated for the ratio values (propor-
tions) using the QuickCalcs Graphpad software. Analyses were
performed using Prism ver. 6.07 (Graphpad Inc., La Jolla, CA).3. Results
3.1. Peptide structure prediction
The helical content of peptide p5 and modiﬁed derivatives,
p5(sheet), p5(coil), and p5(Pro3) in PBS was predicted using the helix/Fig. 1. Predicted secondary structure of peptides used in this study. Peptide p5 was pre
p5(Pro3) were random coils or disrupted helices. Structures were generated using the onl
v4.0.4 (Swiss Institute of Bioinformatics).coil transition theory for monomeric peptides, in the Agadir al-
gorithm (Table 1; [28,29]). In the absence of ligand, the helicity of
all peptides was predicted to be lowwith peptide p5 having 2.6%
helix and the other peptides o0.3% helix. Secondary structure
models for each peptide were generated using the iTASSER soft-
ware package (Fig. 1; [30,31]). Peptide p5 was predicted to adopt a
helical conﬁguration (Fig. 1). Although iTASSER cannot accurately
predict the structure of D-amino acid peptides, given that peptide
p5(D) has the same amino acid sequence but synthesized with D-
amino acids, we posited that it would adopt a similar helix with
but with dextro-chirality. In contrast to p5, p5(sheet) was found to
adopt an extended sheet motif; whereas, p5(coil) appeared un-
structured and p5(Pro3) favored a helical motif but the introduction
of prolines residues hindered extensive coil formation (Fig. 1).
3.2. Surface plasmon resonance
To compare the binding kinetics of each peptide with amyloid
ﬁbrils, a natural ligand of peptide p5, we used surface plasmon
resonance with synthetic AL ﬁbrils composed of rVλ6Wil protein
as the substrate (Fig. 2). The data were ﬁt to a simple Langmuir 1:1
(Table 2) and a more complex, two-state binding (Table 3) equa-
tion. Peptides p5 and p5(sheet) bound equivalently with similarly
high response unit values (RU); although, p5 was predicted to be
10% higher than p5(sheet) based on both ﬁtting models. The es-
timated KD values for p5 and p5(sheet) at 4–15 nM and 10–25 nM,
respectively, depending on the ﬁtting model, were similar. Ad-
ditionally, peptide p5(D) had a predicted KD for rVλ6Wil ﬁbrils of
5–22 nM, but the estimated maximum binding to the ﬁbrils
(RUmax) was 50% less than that of p5 or p5(sheet). Peptides p5(coil)
and p5(pro3) had the lowest binding values, 75% lower RUmax as
compared to p5 (Table 2). The KD for these two peptides was the
lowest, estimated to be 20–70 nM. The extent of binding of each
peptide to rVλ6Wil ﬁbrils, in terms of RU, indicated that:
≈ > > =( ) ( ) ( ) ( )p p p p p5 5 5 5 5sheet D coil Pro3
Both ﬁtting equations reported herein yielded low χ2 values as
an indication of a good ﬁt to the model (Tables 2 and 3). However,dicted to be α-helical whereas p5(sheet) was an extended sheet. Peptide p5(coil) and
ine prediction program, I-TASSER, and rendered using DeepView/Swiss-PDBViewer
Fig. 2. The binding of p5 and p5 peptide analogues to synthetic AL-related light
chain ﬁbrils by using surface plasmon resonance. Peptide binding to rVλ6Wil ﬁbrils
was monitored using 300 nM of analyte in HBS-EP buffer, pH 7.4. Peptides p5
(black), p5(sheet) (green) and p5(D) (red) bound the ﬁbrils in greater amounts than
p5(coil) (orange) and p5(Pro3) (blue). Sensorgrams were analyzed using both a simple
Langmuir model and a two-state binding model.
Table 2
Kinetic SPR parameters for the binding of 300 nM peptide to synthetic rVλ6Wil
ﬁbrils using a Langmuir isotherm.
Peptide ka (1/Ms) kd (1/s) Rmax (RU) KD (M) Chi2
p5 1.2Eþ05 4.4E04 71.5 3.7E09 11.3
p5(D) 3.6Eþ05 1.9E03 36.5 5.4E09 1.36
p5(sheet) 3.4Eþ05 3.4E03 63.0 1.0E08 1.32
p5(coil) 7.7Eþ04 1.4E03 18.9 1.8E08 0.61
p5(Pro3) 8.3Eþ04 2.1E03 17.6 2.5E08 0.29
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values. This ﬁnding indicated that a conformational change in the
peptide may be occurring upon binding to the ﬁbril ligand.
3.3. CD analysis of peptides in TFE
To study the secondary structure of the peptides and structural
transitions that may occur, we initially performed CD spectroscopy
in physiological saline and following addition of increasing con-
centrations of TFE, which induces secondary structure in peptides
(Fig. 3). The structure of peptide p5(D) in PBS, pH 7.5 was char-
acterized by a maxima at 200 nm and a week maxima at 222 nm
(Fig. 3A). Similar, albeit L-amino acid spectra, were observed for
p5(sheet), p5(coil) and p5(Pro3), with minima at 200 nm and
222 nm (Fig. 3A). Upon addition of TFE to a ﬁnal concentration of
40%, the spectra of p5(D) and p5(sheet) with a shift in the 200 nm
maxima/minima toward 207 nm and a pronounced relative in-
crease in the intensity at 222 nm; however, the p5(coil) and p5(Pro3)
were unaltered (Fig. 3A). Addition of TFE induced a helical sec-
ondary structure in peptide p5(D) with a transition midpoint of
16% TFE (Fig. 3B, red). In contrast, the structural transition of
p5(sheet) required greater concentrations of TFE, as evidenced by
the shift at 222 nm, which did not occur until 20% TFE and was notTable 3
Kinetic SPR parameters for the binding of 300 nM peptide to synthetic rVλ6Wil ﬁbrils u
Peptide ka1 (1/Ms) kd1 (1/s) ka2 (1/s)
p5 4.8Eþ05 0.203 0.0315
p5(D) 5.5Eþ05 0.052 7.4E03
p5(sheet) 4.2Eþ05 0.026 7.0E03
p5(coil) 7.5Eþ04 0.001 7.9E06
p5(Pro3) 1.2Eþ05 0.045 0.0122complete at 40% TFE (Fig. 3B, green).
3.4. CD analysis of peptides in the presence of enoxaparin
To study further the structural transitions of the peptides upon
interaction with a ligand, we used a second natural substrate, low
molecular weight heparin (enoxaparin), in the CD analysis (Fig. 4).
The effect of increasing concentrations of enoxaparin on peptides
p5 and p5(D) was a transition to a helical motif with double
minima observed at 207 nm and 222 nm for p5 and chirally-
equivalent maxima for p5(D) (Fig. 4A). The midpoint for the tran-
sition was estimated to be 0.5 mg/mL (100 mM) enoxaparin
(Fig. 4B). In contrast, enoxaparin was a more potent agent for
p5(sheet), which adopted a sheet conformation with a maxima at
202 nm and a minima at 216 nm upon addition of only 0.15 mg/mL
of enoxaparin (Fig. 4B, green). The midpoint of the structural
transition, based on the 216 nm shift in CD spectra, was estimated
to be 0.03 mg/mL (7 mM) enoxaparin (Fig. 4B, green). En-
oxaparin addition to peptides p5(coil) or p5(Pro3) had no effect upon
the secondary structure (Fig. 4). The propensity for heparin bind-
ing, based upon the midpoint of the structural transition varied for
the peptide series according to:
> = > =( ) ( ) ( ) ( )p p p p p5 5 5 5 5sheet D coil Pro3
3.5. Binding of peptide to amyloid ﬁbrils, extracts and tissue
homogenates
We next studied the interaction of the peptides, when radio-
iodinated, with synthetic amyloid ﬁbrils or human amyloid ex-
tracts either in PBS or 1 M NaCl, as well as murine, amyloid-laden
liver homogenates in PBS, using a pulldown assay (Fig. 5, Table 4).
In the pulldown assay, 125I-labeled peptides all bound rVλ6Wil, Aβ
(1-40) and IAPP synthetic ﬁbrils in PBS (Fig. 5A, dark bars); how-
ever, p5(coil) and p5(Pro3) were generally less effective as compare
to peptide p5, especially when IAPP ﬁbrils were used as the sub-
strate. Binding to synthetic ﬁbrils was greatly, but variably, di-
minished in the presence of 1 M NaCl (Fig. 5A, light bars). Peptides
p5(D) and p5(sheet) bound all three ﬁbril types in a similar manner
to peptide p5 (Fig. 5A). The ratio of binding for each peptide in PBS
to that in 1 M NaCl was calculated as a measure of the relative
afﬁnity of the peptide for the substrate, assuming the reaction was
dominated by electrostatic interactions (Table 4). The calculated
binding ratios for 125I-p5, 125I-p5(D) and 125I-p5(sheet) were greater
than 125I-p5(coil) and 125I-p5(Pro3) for all amyloid ﬁbrils evaluated
(Table 4).
Binding to ALκ, ALλ and ATTR human amyloid extracts was
decreased for all peptides relative to the synthetic ﬁbrils (Fig. 5B).
Notably, 125I-p5(sheet) exhibited the greatest binding to all sub-
strates (97%, 87%, and 80% bound) with 125I-p5(coil) and 125I-p5(Pro3)
having the lowest extract binding (7%, 14%, and 12% for
125I-p5(Pro3)). Binding of all peptides to amyloid extracts in a milieu
of 1 M NaCl was signiﬁcantly reduced to o3% (Fig. 5B).
The peptide interactions with AA amyloid-laden (dark bars)
and WT (light bars) murine liver tissue homogenates weresing a two-state binding model.
kd2 (1/s) Rmax (RU) KD (M) Chi2
1.1E03 97.6 1.5E08 0.57
1.7E03 63.4 2.2E08 0.27
2.8E03 89.7 2.5E08 0.34
1.5E05 19.0 3.4E08 0.61
2.4E03 31.5 7.1E08 0.23
Fig. 3. Structural analysis of peptides, by circular dichroism, in response to increasing concentrations of TFE. A) CD spectra of peptides p5(D), p5(sheet), p5(coil), and p5(Pro3) in
the presence of increasing concentrations of TFE up to 40% v/v. B) TFE-induced structural transitions of p5(D) (red) and p5(sheet) green are evidenced by changes in the molar
elipticity at 222 nm for each peptide. Peptides p5(Pro3) (gray) and p5(coil) (blue) were not structured in the presence of up to 4040% TFE.
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amyloidosis. The data indicated that peptides 125I-p5(D) (92%) and
125I-p5(sheet) (92%) bound the amyloid in greater amounts as
compared to peptide 125I-p5 (52%; Fig. 5C). The reactivity of
125I-p5(coil) and 125I-p5(Pro3) was much lower, 21% and 11%, re-
spectively, relative to the other peptides (Fig. 5C). The binding to
amyloid-free, WT liver, was signiﬁcantly lower than the AA-liver
homogenate at 9%, the maximal value, observed for 125I-p5(sheet)
(Fig. 5C).
3.6. Competition binding assays
To further interrogate the binding of the peptides with amyloid
ﬁbrils, we examined whether the binding of radioiodinated pep-
tides p5(D), p5(sheet), p5(coil) and p5(Pro3) could be inhibited by an
excess of peptide p5 (Fig. 6). In the homologous reaction, a 1000-
fold molar excess of p5 inhibited the binding of 5 ng of 125I-p5 to
25 mg of rVλ6Wil ﬁbrils by 95% in the pulldown assay (Fig. 6).
Inhibition of 125I-labeled p5(D), p5(coil) and p5(Pro3) binding to
rVλ6Wil ﬁbrils was similarly reduced by 80%, 80% and 99%, re-
spectively, in the presence of peptide p5. In contrast, a 1000-fold
molar excess of p5 reduced the binding of 125I-p5(sheet) to ﬁbrils by
only15%.
3.7. Molecular dynamics simulations
To provide further insight into the binding of p5(sheet) and
p5(coil) to ﬁbrils, the interactions with Aβ ﬁbrils were modeled
using molecular dynamics simulations and compared to that of p5
(Fig. 7; Table 5). The computer modeling and simulations revealed
that peptide p5 and p5(sheet) bound to the longitudinal face of the
ﬁbril and that the interaction was dominated by multivalent
electrostatic interactions between the lysine side chains and, in
this case, Glu21 in the Aβ peptide (Fig. 7). The molecular me-
chanics combined with the Poisson–Boltzmann and surface area(MM/PBSA) method is commonly used to estimate the binding free
energy of two molecules. However, it contains several crude ap-
proximations, for example, the lack of conformational entropy and
contribution from water molecules in the binding site. Therefore,
the MM/PBSA method is only semi-quantitative. Moreover, due to
the enthalpy-entropy compensation, the MM/PBSA results (only
the enthalpy part) can deviate signiﬁcantly from the true binding
free energies, so they are not accurate for calculating absolute Kd
values. Instead, the MM/PBSA approach is very useful in predicting
the trend of relative binding in a series of compounds. For these
reasons, we report our values as “apparent” ΔG. Although the in-
teraction was dominated by an apparent ΔGPB,elec (50 kcal/mol,
for both peptides), van der Waals interactions (33 kcal/mol)
were also signiﬁcant (Table 5). The apparent binding free energy
for p5 and p5(sheet), 96 and 89k kcal/mol, respectively, was
greater than that for the binding of p5(coil) to the ﬁbrils (32 kcal/
mol). The modeling data for p5(coil) indicated that only three salt
bridges were formed between the ﬁbril and this peptide (Fig. 7).4. Discussion
4.1. Heparin-reactive peptides as speciﬁc amyloid targeting agents
Amyloid diseases are complex and heterogeneous. There are no
non-invasive methods to detect and quantify these deposits in the
USA. We have identiﬁed synthetic peptides capable of binding two
of the major components of all tissue amyloid deposits, namely the
proteinaceous amyloid ﬁbrils and the associated hypersulfated he-
paran sulfate proteoglycans [9,11,15] for use for imaging and ther-
apy. Both constituents are ionic polymers composed of repeating
elemental units - amyloidogenic precursor proteins, and acidic
disaccharides, respectively. The prototypic peptide initially identi-
ﬁed as exhibiting speciﬁc amyloid binding was designated p5, a
synthetic, polybasic peptide initially develop in silico as a heparin
Fig. 4. Structural analysis of peptides in response to increasing concentrations of low molecular weight heparin (Enoxaparin). (A) Structural changes evidenced in circular
dichroism spectra of peptides in the presence of increasing concentrations of enoxaparin up to 1.5 mg/mL. For peptide p5(sheet), enoxaparin was added up to 0.15 mg/mL.
(B) Helicity was induced in peptides p5 (white) and p5(D) (red). However, peptides p5(Pro3) (gray) and p5(coil) (blue) were less structured and peptide p5(sheet)(green) adopted
a β-sheet conﬁguration, as evidenced by changes in molar elipticity at 222 nm and 216 nm, respectively.
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required for amyloid reactivity of polybasic peptides, we generated
an all-D enantiomer of p5, a peptide with a propensity for β-sheet
formation and, ﬁnally, analogues with disrupted helical secondary
structure. Each of these structural changes will cause subsequent
changes in the distribution of cationic amino acid sidechains. We
hypothesized that these data will guide novel amyloid-reactive
peptide design with enhanced targeting capabilities.4.2. Binding of p5 analogues with disrupted helices – the importance
of ligand charge
Heparin binds basic peptides and induces a secondary structure
in the latter that can be readily detected by using CD spectroscopy
[16,32,33]. The binding of peptides to heparin is strongly inﬂu-
enced by the propensity to adopt an α-helical structure creating a
favorable spatial orientation of the basic amino acids in the
Fig. 5. Analysis of 125I-labeled peptide binding to amyloid-related substrates using a pulldown assay. Binding of 125I-labeled peptides to synthetic ﬁbrils (A), human AL and
ATTR amyloid extracts (B), or liver homogenates from WT and amyloidotic mice (C) was measured in PBS (dark bars) and 1 M NaCl (white bars). Statistical analysis of the
binding data in PBS was performed using a Bonferroni multiple comparison ANOVA (po0.01). Brackets indicate which comparisons were NOT signiﬁcantly different from
the p5 value. All other comparisons with p5 were deemed signiﬁcant.
Table 4
Relative efﬁciency of peptide binding to synthetic amyloid ﬁbrils and human
amyloid extracts based on the ratio of 1 M/0.15 M pulldown data.
Substrate 125I-p5 125I-p5 (D) 125I-p5 (sheet) 125I-p5 (coil) 125I-p5 (Pro3)
rVλ6Wil ﬁbril 0.11 0.30 0.35 0.02 0.01
Aβ(1–40) ﬁbril 0.57 0.29 0.21 0.07 0.01
IAPP ﬁbril 0.26 0.30 0.20 0.12 0.07
ALκ4 extract 0.004 0.035 0.017 0.040 0.030
ALλ1 extract 0.013 0.015 0.028 0.021 0.022
ATTR extract 0.008 0.032 0.026 0.059 0.018
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monstrated that the speciﬁc binding of heparin-reactive peptides
to amyloid in vivo is similarly governed by helicity and chargespacing. Peptide p5 binds heparin with a KD of 0.64 mM [17], and
reacts with AA amyloid-laden tissue with an estimated high afﬁ-
nity binding site with a KD of 0.5 mM [10].
Substituting glycine (p5(coil)) or proline amino acids (p5(Pro3))
into the p5 peptide sequence resulted in a decrease in helical
propensity as predicted by both the Agadir (Table 1) algorithm and
iTASSER methods (Fig. 1). The former uses helix/coil transition
theory, and the latter generates structures based on sequence
alignment and threading using homologous sequences found in
the x-ray crystal structure database. In contrast to p5, these sub-
stitutions rendered peptides p5(coil) and p5(Pro3) incapable of
adopting a helical motif in PBS in the presence of TFE or following
addition of the ligand, enoxaparin. However, both p5(coil) and
p5(Pro3) remained capable of binding synthetic amyloid ﬁbrils
composed of rVλ6Wil (AL amyloid) or Aβ(1-40) (Aβ amyloid).
Fig. 6. Binding of 125I-labeled peptide to rVλ6Wil ﬁbrils in the presence of excess
p5 using a completion pulldown assay. Radiolabeled peptides (5 ng) were in-
cubated with 25 mg of synthetic rVλ6Wil ﬁbrils in the presence of 1000 M excess of
peptide p5. The mean % bound peptide (relative to peptide in the absence of
competitor; n¼2 replicates) with 95% conﬁdence interval is plotted.
Fig. 7. Molecular dynamics simulation of peptide p5, p5(sheet) and p5(coil) binding to Aβ
ﬁbril (PDB # 2BEG) were taken from molecular dynamics trajectories equilibrated after
Lower panels show images with space-ﬁlled interacting side chains on the surface o
estimated free energy of binding (ΔG) is shown for each modeled interaction.
Table 5
Thermodynamic parameters estimated from molecular dynamic simulations for
peptide p5, p5(sheet) and p5(coil) binding to Aβ(17-42) ﬁbrils computed using the
MM-PB/SA method.
ΔEVDWa ΔGPB, elec ΔGnonpolar ΔGbind (app)
p5 35.3876.19 53.5075.18 7.3170.40 96.20
p5(sheet) 31.2679.67 49.1078.55 8.4170.72 88.77
p5(coil) 26.8777.13 0.7273.94 4.7870.63 32.37
a Where: ΔEVDW is the van der Waals contribution; ΔGnonpolar is the nonpolar
component of the solvation free energy estimated by surface area, and; ΔGPB, elec is
the electrostatic component of the apparent total binding energy, ΔGbind (app).
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p5(Pro3) to Aβ(1-40) ﬁbrils (Fig., 5A). This dichotomy supports our
hypothesis that p5-like basic peptides bind to sulfated glycosa-
minoglycans and amyloid ﬁbrils in two distinct ways.
This may be due to differences in the nature of the substrates,
heparin or HS, and synthetic amyloid. For example, synthetic
amyloid ﬁbrils composed of rVλ6Wil and Aβ(1-40) are not in-
dependent linear arrays. Rather, synthetic ﬁbrils are complex ag-
gregated matrices, i.e. a lattice, with surface charge density that is
dependent on the orientation of the proteins comprising the ﬁbrils
and the amino acid side chains exposed on the ﬁbril surface. In
some regards, the surface presented by amyloid ﬁbrils used in this
study may be approximated by a rigid 2-dimensional charged
surface array or a synthetic phospholipid membrane [34]. The
planar charge distribution on the amyloid surface may allow non-
helical, protean peptides such as p5(coil) and p5(Pro3) to bind syn-
thetic rVλ6Wil and Aβ(1-40) ﬁbrils, possibly by interacting with
charges of multiple ﬁbrils. In contrast, the inability of p5(coil) and(17-42) amyloid-ﬁbrils. Images of peptide p5, p5(sheet) and p5(coil) to the Aβ(17-42)
more than 100 ns each. The upper panels show stick rendering of the interaction.
f the ﬁbril. Images were rendered using DeepView/Swiss-PDBViewer v4.0.4. The
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binding to the presumably monodisperse, linear, enoxaparin. In-
terestingly, peptides p5(coil) and p5(sheet) did not bind well to IAPP
ﬁbrils (Fig. 5), as compared to p5. The IAPP peptide differs from
rVλ6Wil and Aβ(1-40) sequence because it has no acidic amino
acids – only an unprotected carboxylate at the C-terminal pro-
viding negative charge for interaction with the peptides. There-
fore, the IAPP ﬁbril “lattice” will have a much reduced surface
charge density, relative to the other ﬁbrils, which may not support
efﬁcient binding of the two helix-disrupted peptides. These data
demonstrate the importance of the surface charge density pre-
sented by the amyloid ﬁbrils on peptide binding.
4.3. Binding of peptides to amyloid is dominated by electrostatic
interactions
The binding of all p5-related peptides to synthetic amyloid ﬁbrils
and amyloid extracts was decreased by the addition of 1 M NaCl
indicative of an electrostatically-driven interaction (Fig. 5). Human
amyloid extracts differ from synthetic ﬁbrils due to the presence of
accessory molecules. The presence of HS proteoglycans can serve as
an additional target for the peptides. However, constituents such as
apolipoproteins and serum amyloid P component may block poten-
tial binding sites and hinder peptide binding. Relative to synthetic
ﬁbrils, the interaction of all the peptides was markedly reduced when
human AL or ATTR extracts were used as a substrate, likely due to
this enhanced complexity. The notable exception was p5(sheet), which
bound the amyloid extracts as efﬁciently as synthetic ﬁbrils. The
binding of all peptides with amyloid extract was completely inhibited
by 1 M NaCl. This contrasts starkly with the effect of NaCl on the
binding with pure synthetic ﬁbrils, which was not completely in-
hibited. This suggests that peptide amyloid interactions are com-
pletely dominated by electrostatic interactions and may pre-
ferentially involve the HS moieties. In contrast, amyloid ﬁbril-peptide
interactions likely involve both electrostatic and as well as non-ionic
interactions. This is supported by molecular dynamics simulations
which the apparent values calculated indicated that ΔEVDW and
ΔGnonpolar account for 50% of the estimated binding energy
(ΔGbind) of the p5 and p5(sheet) interaction with Aβ(17-42) ﬁbrils and
essentially all the energy for the weak association of p5(coil) with the
synthetic ﬁbril model (Table 5). Thus, we conclude that, whereas the
binding of peptides with heparin are dominated by electrostatic in-
teractions [14,17,33,35], reactivity with synthetic amyloid ﬁbrils also
involves a signiﬁcant non-electrostatic component.
4.4. D-amino acid p5 binds amyloid substrate effectively in vitro
Incorporation of D-amino acids into synthetic peptides of bio-
medical interest prevents proteolysis in vivo, enhances circulating
half-life and prevents deiodination of tyrosine amino acids by
dehalogenases in the liver and kidneys [36-38]. Therefore, an all-D
enantiomer of peptide p5 (p5(D)) may yield an enhanced amyloid
imaging agent. Peptide p5(D) bound heparin with induction of an
α-helix and, like p5, reacted with synthetic ﬁbrils and amyloid
extracts with similar, or greater efﬁcacy, with the exception of Aβ
(1-40) ﬁbrils (Table 4). The binding site of p5(D) on rVλ6Wil ﬁbrils
is predicted to be the same as for p5, based on competition studies,
which showed that p5 competed equally for binding of 125I-p5 or
125I-p5(D). Therefore, the all-D enantiomer of p5, when radio-
iodinated, may image amyloid in vivo as well as p5 but with en-
hanced stability as compared to p5.
4.5. The β-sheet peptide conﬁguration binds amyloid effectively in
vitro
The binding of p5 with heparin involves a linear alignment oflysine sidechains along a helical structure that favors multivalent
interaction with the sulfate moieties presented by the heparin
structure. To further assess the requirement for helicity in amyloid
binding peptides, we designed p5(sheet) using valine and threonine
residues as spacers between the lysine residues (Table 1). This
sequence should have a propensity to adopt β-sheet [39]. The
p5(sheet) peptide bound heparin more efﬁciently than peptide p5.
Additionally, p5(sheet) bound all amyloid-related substrates sig-
niﬁcantly better than p5. When peptides adopt a helical secondary
structure with a –KAKAKA-repeat, the binding to heparin yields a
KD of 62.5 mM (Wang, BBA 2009), which is 1000-fold weaker than
the heptad motif in peptide p5. In contrast, our data suggest that
the p5(sheet) peptide with a –KVKTK- repeat motif binds heparin
with a 10-fold greater afﬁnity than p5 (see Fig. 4). These data
suggest that the sheet conformation, with alternating lysine re-
sidues, results in a linear array of charged sidechains that can ef-
fectively interact with linear heparin and HS moieties as well as
the charged planar array presented by synthetic ﬁbrils. Molecular
dynamic simulations of the interaction of p5(sheet) with a prototype
Aβ(17-40) amyloid ﬁbril structure demonstrated multivalent
electrostatic interactions between the lysine side chains of the
peptide and the aspartate side chains that were spaced regularly
along the longitudinal axis of the ﬁbril, due to the repeating Aβ
elements (Fig. 7). Indeed, despite the difference in charged amino
acid spacing found in p5 and p5(sheet), both peptides were pre-
dicted to interact with juxtaposing aspartate moieties, based on
the simulation. The modeling data are somewhat counter-intuitive
since we have demonstrated in vitro that peptide p5(sheet) likely
occupies sites on amyloid ﬁbrils that are distinct from the p5
binding site, as its reactivity was not effectively inhibited by an
excess of p5 (Fig. 6). By way of reconciling the modeling and
binding studies, it seems likely that p5(sheet) may have a higher
afﬁnity for the ﬁbrils and, therefore, competes well for the binding
of p5. Alternatively, in the presence of an excess of bound p5, the
p5(sheet) may bind at alternative sites on the ﬁbrils, something that
cannot be accessed by simulations. Given the β-sheet propensity
of p5(sheet), this peptide may be able to intercalate into the amyloid
ﬁbrils, which are composed of precursor proteins with a β-sheet
conformation. Regardless, p5(sheet) is a novel heparin-reactive
peptide that can be further studied for its utility in amyloid-
targeting.5. Summary
Amyloid-reactive peptides have great potential as speciﬁc
amyloid-targeting agents that can be adapted for imaging the
pathology and, potentially, as therapeutics. Peptide p5 is the pro-
totypic heparin-reactive, synthetic, α-helical reagent capable of
very speciﬁc amyloid binding in vivo. The helical secondary
structure of p5 is important for the binding to heparin and amy-
loid extracts. An all-D enantiomer of p5, which may be more stable
in vivo, exhibited enhanced amyloid reactivity. In addition, the
p5(sheet) peptide, with a propensity for β-sheet formation in the
presence of ligand, displayed enhanced reactivity to heparin and
signiﬁcantly better amyloid binding, as compared to p5. Our data
suggest that polybasic peptides with a β-sheet propensity afford a
new class of reagents with enhanced binding properties for mul-
tiple, biomedically relevant needs, i.e. the neutralization of small
molecular weight heparin and as agents for imaging and treating
amyloid in patients with systemic amyloidosis.Acknowledgments
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